Results 161 to 170 of about 25,910 (264)

Metastatic Urachal Carcinoma With Microsatellite Stability and Low Tumor Mutational Burden Achieving a Durable Response to Pembrolizumab After Platinum Failure

IJU Case Reports, Volume 9, Issue 6, November 2026.
ABSTRACT Introduction Urachal carcinoma is a rare and aggressive malignancy with no established systemic therapy after platinum failure. Evidence for immune checkpoint inhibitors (ICIs) remains limited, particularly in tumors without established favorable biomarkers such as microsatellite instability‐high status or high tumor mutational burden.
Fumihiro Ito, Koki Kobayashi, Gaku Hayashi, Shunsuke Kamijo, Takashi Fujita   +4 more
wiley   +1 more source

Artificial intelligence for translational personalized neoantigen cancer vaccine development. [PDF]

J Biomed Sci
Wei CY, Lin HC, Wu CJ, Kuo CN, Chang CM, Chou WH, Chou SP, Feng SH, Huang WC, Jiang S, Fairfax BP, Lee KY, Chang WC.   +12 more
europepmc   +1 more source

Durable Complete Response to Pembrolizumab for Postoperative Nodal Recurrence of Lynch Syndrome–Associated Upper Tract Urothelial Carcinoma: A Case Report

IJU Case Reports, Volume 9, Issue 6, November 2026.
ABSTRACT Introduction Germline mutations in mismatch repair genes cause Lynch syndrome and are associated with upper tract urothelial carcinoma (UTUC). Tumors with deficient mismatch repair (dMMR) or microsatellite instability–high (MSI‐H) may respond favorably to immune checkpoint inhibitors.
Kaya Atagi, Shinkuro Yamamoto, Nobutaka Shimizu, Mitsuko Iguchi, Ryu Shigehisa, Tomoya Nao, Tsutomu Shimamoto, Hideo Fukuhara, Satoshi Fukata, Keiji Inoue   +9 more
wiley   +1 more source

Neoantigen prediction and the need for validation [PDF]

Nature Biotechnology, 2017
Antonella, Vitiello, Maurizio, Zanetti
openaire   +2 more sources

Personalised neoantigen vaccines for precision oncology in Southeast Asia: clinical opportunities, infrastructure challenges, and policy perspectives. [PDF]

Front Immunol
Gao Y, Wang Y, Li J.
europepmc   +1 more source

The FOXQ1/SSBP2 Regulatory Axis Drives Malignant Progression of Melanoma

Molecular Carcinogenesis, Volume 65, Issue 11, Page 1459-1477, November 2026.
ABSTRACT Melanoma is a highly aggressive skin cancer with poor prognosis, often linked to excessive UV exposure. Despite advancements in immunotherapy and targeted treatments, melanoma's invasiveness and metastatic potential remain significant challenges.
Xiaoyu Zhang, Yu Hou, Jiahui Liu, Yuehua Han, Jiangang Feng   +4 more
wiley   +1 more source

Bispecific NK‐Cell Engager Targeting TP53 Mutation Through Integration of a TCR‐mimic Antibody

MedComm, Volume 7, Issue 11, November 2026.
Most existing NK cell engagers (NKCEs) target tumor‐associated antigens (TAAs), risking on‐target, off‐tumor toxicity. We engineered a novel NKCE termed C33×CD16, a single‐chain diabody (scDb) constructed by fusing TCR‐mimic antibody C33‐Ab (targeting p53R175H/HLA‐A*02:01) to the scFv of 3G8 (anti‐CD16 antibody) (a).
Hanfei Wu, Zhe Zhao, Li Zhang, Xuan Xiong, Mengdie Yang, Weiping Ge, Danyue Zhi, Xiaobin Cao, Chuanqian Yi, Yong Qiao, Junjun Cao, Yan Mei, Shiping Jiao, Quan Liu, Hao Zhou, Zhongjuan Xu, Guangli Suo   +16 more
wiley   +1 more source

The Central Role of HLA Class II-Restricted Helper Neoantigen Vaccines in Cancer Immunotherapy. [PDF]

Cancers (Basel)
Morisaki T, Morisaki T.
europepmc   +1 more source

Atherosclerosis: From Pathogenesis to Therapeutic Interventions

MedComm, Volume 7, Issue 11, November 2026.
The diagram outlines the core mechanisms driving atherosclerosis, including endothelial dysfunction, inflammatory responses, phenotypic switching of smooth muscle cells, and the gut–vascular axis. It also presents the corresponding therapeutic approaches now under development, such as gene therapies, immunotherapies, and nanotechnology platforms ...
Enge Zhou, Chenxi Zhan, Yuting Li, Yi Zeng, Renfei Luo, Xin Ouyang, Shixing Liu, Renqiang Yang, Nianlong Yan, Long Jiang   +9 more
wiley   +1 more source

mRNA Vaccines as Novel Immunotherapeutic Approaches in Gastrointestinal Cancers. [PDF]

Cells
Ghidini M, Novazzi F, Denaro N, Petrillo A, Ratti M, Salati M, Malvaso R, Di Marco L, Parisi A, Hahne JC.   +9 more
europepmc   +1 more source